OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 122 filers reported holding OCULAR THERAPEUTIX INC in Q2 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $70,635 | -1.9% | 13,689 | -20.8% | 0.00% | – |
| Q3 2022 | $72,000 | -51.4% | 17,291 | -53.1% | 0.00% | -100.0% |
| Q2 2022 | $148,000 | -25.6% | 36,891 | +85.3% | 0.00% | 0.0% |
| Q3 2021 | $199,000 | -59.6% | 19,913 | -42.6% | 0.00% | -50.0% |
| Q2 2021 | $492,000 | +49.5% | 34,681 | +73.2% | 0.00% | 0.0% |
| Q1 2021 | $329,000 | +53.7% | 20,026 | +94.1% | 0.00% | 0.0% |
| Q4 2020 | $214,000 | -75.9% | 10,315 | -91.2% | 0.00% | -83.3% |
| Q3 2020 | $889,000 | -28.5% | 116,846 | -21.7% | 0.01% | -40.0% |
| Q2 2020 | $1,243,000 | +886.5% | 149,257 | +487.1% | 0.02% | +566.7% |
| Q1 2020 | $126,000 | +186.4% | 25,424 | +77.2% | 0.00% | – |
| Q3 2019 | $44,000 | -55.6% | 14,348 | -35.5% | 0.00% | -100.0% |
| Q4 2017 | $99,000 | -32.2% | 22,243 | +41.6% | 0.00% | -33.3% |
| Q2 2017 | $146,000 | -71.4% | 15,703 | -74.3% | 0.00% | -85.7% |
| Q4 2016 | $510,000 | – | 60,985 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,804,788 | $15,105,000 | 43.34% |
| Versant Venture Management, LLC | 2,215,384 | $8,795,074,000 | 2.90% |
| Opaleye Management Inc. | 1,900,000 | $7,543,000 | 2.09% |
| SV Health Investors, LLC | 628,236 | $2,494,000 | 1.46% |
| Endurant Capital Management LP | 716,124 | $2,843,000 | 1.12% |
| DELTEC ASSET MANAGEMENT LLC | 824,747 | $3,274,000 | 0.72% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $583,000 | 0.08% |
| Jump Trading, LLC | 39,255 | $156,000 | 0.05% |
| Man Group plc | 1,723,456 | $6,842,000 | 0.03% |
| JGP Global Gestao de Recursos Ltda. | 13,880 | $55,000 | 0.02% |